Clovis Oncology (CLVS) Gains Again Amid Continued Takeover Chatter

Clovis Oncology (CLVS) takeover chatter may be overdone - TheStreet

Clovis Oncology (NASDAQ: CLVS) takeover chatter may be overdone - TheStreet

LINK

Clovis Oncology's (CLVS) Price Target Raised to $50 at SunTrust Robinson

SunTrust Robinson Humphrey maintained a Buy rating on Clovis Oncology (NASDAQ: CLVS) and raised its price target to $50.00 (from $38.00).

For an analyst ratings summary and ratings history on Clovis Oncology click here. For more ratings news on Clovis Oncology click here.

Shares of Clovis Oncology closed at $38.36 yesterday.

Janney Montgomery Scott Downgrades Clovis Oncology (CLVS) to Neutral

Janney Montgomery Scott downgraded Clovis Oncology (NASDAQ: CLVS) from Buy to Neutral with a price target of $36.00 (from $30.00).

For an analyst ratings summary and ratings history on Clovis Oncology click here. For more ratings news on Clovis Oncology click here.

Shares of Clovis Oncology closed at $34.83 yesterday.

Clovis Oncology (CLVS) PT Raised to $45 at Stifel Amid De-Risking Events

Stifel analyst Thomas Shrader reiterated a Buy rating and raised his price target on Clovis Oncology (NASDAQ: CLVS) to $45.00 (from $30.00), saying recent events de-risk the stock.

Shrader commented, "A series of events in the last few weeks have seemed to de-risk the Clovis story including the acceptance of the rucaparib NDA, the lack of an ODAC panel and a final update for olaparib that suggests that PARP inhibitors may never show an OS benefit in the ovarian cancer (OC) maintenance setting (not... More

Credit Suisse Upgrades Clovis Oncology (CLVS) to Outperform on Takeout Potential

Credit Suisse upgraded Clovis Oncology (NASDAQ: CLVS) from Neutral to Outperform with a price target of $41.00 (from $19.00).

Analyst Kennen MacKay commented, "We upgrade CLVS to OUTPERFORM from NEUTRAL and increase our target price to $41 from $19. We move our valuation methodology to an M&A DCF from a standard DCF on the potential for CLVS to... More

Clovis Oncology (CLVS) Adds to Intra-Day Gains on Rampant M&A Chatter

Clovis Oncology (NASDAQ: CLVS) adds to intra-day rumor-fueled gains after-hours. Shares are up 6% after-hours after gaining 12.7% intra-day on increased takeover chatter.

UPDATE: Clovis Oncology (CLVS) Shares Spike to Session Highs Amid Chatter (GILD) (LLY)

(Updated - September 20, 2016 3:00 PM EDT)

Clovis Oncology (Nasdaq: CLVS) shares spike to session highs.

UPDATE - Market chatter recently speculated that Clovis has been eyed as a potential target for Gilead Sciences (NASDAQ:... More

Clovis Oncology (NASDAQ: CLVS) calls active as shares spike

Clovis Oncology (NASDAQ: CLVS) October 30 and 35 calls are active on total call volume of 2,800 contracts (400 puts). October call option implied volatility is at 114, November is at 96; compared to its 52-week range of 63 to 217.